Low-Dose Naltrexone for Hair Loss

Low-dose naltrexone, commonly abbreviated LDN, is an off label use of the prescription medication naltrexone at doses substantially lower than those approved for alcohol and opioid use disorders.

Interest in LDN has grown because low doses may influence inflammatory and immune signaling in ways that differ from the medication’s conventional use as an opioid receptor antagonist. This has led physicians to investigate LDN in chronic inflammatory, autoimmune and pain disorders, including several dermatologic diseases.

In hair loss, however, the evidence is much narrower than online discussions sometimes suggest.

The principal clinical research involves lichen planopilaris, or LPP, and frontal fibrosing alopecia, or FFA, two inflammatory scarring alopecias in which permanent follicular destruction can occur. Small studies have reported improvements in scalp redness, itching, discomfort or apparent disease stability in some patients.

That evidence has important limitations. Most studies are small, many patients received other treatments at the same time and disease activity can fluctuate naturally. Most importantly, the only placebo controlled randomized trial in LPP did not demonstrate that adding LDN to topical clobetasol produced greater overall disease improvement than clobetasol with placebo.

There is currently no convincing clinical evidence establishing low-dose naltrexone as a treatment for ordinary male or female pattern hair loss, telogen effluvium or alopecia areata.

LDN should therefore be viewed primarily as a possible adjunctive treatment for selected inflammatory scarring alopecias, not as a general hair growth medication.

What Is Naltrexone?

Naltrexone is an opioid receptor antagonist.

Standard oral naltrexone is FDA approved for the treatment of alcohol dependence and for blocking the effects of externally administered opioids in appropriately detoxified patients.

The conventional oral dose used for those indications is commonly 50 mg daily.

Low-dose naltrexone uses the same active medication at much smaller doses, generally approximately 1 to 5 mg per day. Hair loss studies have most commonly used approximately 3 mg daily, while some retrospective reports have used doses between approximately 2.5 and 4.5 mg daily.

There is no FDA approved low-dose naltrexone formulation specifically for hair disease or any FDA approved naltrexone indication for a dermatologic hair disorder.

Is Low-Dose Naltrexone FDA Approved for Hair Loss?

No.

Naltrexone itself is an FDA approved prescription medication, but FDA approval does not extend to low-dose naltrexone treatment for:

• Lichen planopilaris
• Frontal fibrosing alopecia
• Alopecia areata
• Male pattern hair loss
• Female pattern hair loss
• Telogen effluvium
• Central centrifugal cicatricial alopecia
• Other scarring alopecias

All of these uses are off label.

There is also no FDA established low-dose naltrexone dose, treatment duration or monitoring protocol for hair loss.

What Does “Low Dose” Actually Mean?

There is no official FDA definition of low-dose naltrexone.

In the dermatology literature, LDN generally refers to oral doses in the approximate range of 1 to 5 mg daily. Three milligrams daily has been used repeatedly in LPP and FFA studies, while doses around 2.5 to 4.5 mg have also been reported.

That does not mean 4.5 mg is automatically more effective than 3 mg.

There are no adequate dose ranging trials in hair disease demonstrating that increasing LDN within this range reliably improves outcomes.

The lowest effective sustainable exposure remains a reasonable principle when treatment is being used experimentally or as an adjunct.

How Might Low-Dose Naltrexone Affect Inflammation?

The mechanism remains incompletely established.

At conventional doses, naltrexone blocks opioid receptors. At much lower doses, researchers have proposed that temporary opioid receptor blockade may produce compensatory changes in endogenous opioid signaling and receptor activity.

Laboratory and translational research has also proposed effects involving Toll-like receptor 4, or TLR4, and other inflammatory pathways.

These mechanisms are biologically interesting, but they remain proposed explanations for LDN’s clinical effects. It has not been established that LDN controls LPP or FFA specifically by blocking TLR4 or through any single defined pathway.

Mechanistic plausibility should not be confused with clinical proof.

Why Has LDN Been Studied for Lichen Planopilaris and Frontal Fibrosing Alopecia?

Lichen planopilaris and frontal fibrosing alopecia are inflammatory scarring disorders of the hair follicle.

Inflammatory immune activity targets structures surrounding the upper portion of susceptible follicles. If that process continues, follicular stem cell structures can be permanently damaged and replaced by scar tissue.

Once a follicle has truly been destroyed by fibrosis, medication generally cannot recreate it.

The objective of treatment is therefore primarily to suppress active inflammation, slow or stop disease progression and preserve follicles that remain viable.

Symptoms such as itching, burning, scalp tenderness, perifollicular redness and scale may provide evidence that inflammation is present, although symptoms and visible redness do not always perfectly reflect ongoing microscopic follicular injury.

LDN has attracted interest because of its proposed anti inflammatory and immunomodulatory activity without functioning as a conventional broad systemic immunosuppressant like methotrexate, cyclosporine or systemic corticosteroids.

That difference does not establish that LDN is safer or more effective. It simply reflects a different pharmacologic approach.

Does LDN Regrow Hair in Scarring Alopecia?

The principal treatment objective in LPP and FFA is usually disease stabilization, not regeneration of follicles already destroyed by fibrosis.

LDN studies have mainly evaluated inflammatory signs, symptoms and measures of disease activity rather than demonstrating robust regrowth of hair in established scarred areas.

There are individual case reports describing notable apparent regrowth during combination treatment involving LDN, including treatment with platelet rich plasma.

Those reports cannot establish that LDN produced the regrowth or that permanently destroyed follicles regenerated. Other treatments were used at the same time, there were no control groups and unusual individual responses should not be generalized to the broader scarring alopecia population.

A calmer scalp, less redness or less itching may be encouraging, but those changes should not automatically be interpreted as proof that additional permanent follicular destruction has stopped.

What Did the First LPP Case Series Show?

An early 2017 report described four patients with lichen planopilaris treated with low-dose naltrexone 3 mg daily.

The authors reported reductions in itching and clinical inflammation as well as apparent slowing of disease progression. All four patients tolerated treatment.

This case series helped generate interest in LDN for inflammatory scarring alopecia.

Four patients without a control group, however, cannot establish efficacy. LPP can fluctuate naturally, and patients with difficult disease frequently receive several treatments simultaneously.

The study should therefore be viewed as hypothesis generating rather than definitive.

What Did the Randomized Placebo Controlled Trial Show?

This is one of the most important studies for understanding LDN realistically.

A randomized controlled trial evaluated patients with lichen planopilaris who received topical clobetasol together with either low-dose naltrexone 3 mg daily or placebo.

Thirty four patients were analyzed over six months.

Disease activity scores decreased over time in the LDN group, but the difference between the LDN and placebo groups was not statistically significant.

The investigators concluded that adding low-dose naltrexone did not improve overall LPP severity beyond what was achieved with topical clobetasol and placebo.

That does not prove that LDN has no biological activity or that no individual patient can benefit.

It does mean that the strongest controlled trial available failed to demonstrate a clear incremental overall benefit.

This should carry more evidentiary weight than uncontrolled case reports.

What Did the One Year Prospective Study Show?

A later prospective open label study evaluated low-dose naltrexone 3 mg daily as adjunctive treatment in patients with LPP and FFA.

Twenty six patients who remained on treatment long enough for the planned analysis were evaluated over one year.

Physician assessed erythema decreased significantly over 12 months, and scale showed some improvement.

However, several other outcomes, including itching, burning or pain and overall scalp involvement, did not demonstrate statistically significant improvement between baseline and 12 months.

The study therefore provides some evidence that LDN may reduce visible inflammatory redness in selected patients.

It does not establish that LDN reliably prevents additional permanent follicular loss. There was no placebo group, patients continued other therapies and some LPP or FFA cases can stabilize naturally.

What Did the Larger Retrospective Study Show?

A later retrospective study examined patients with LPP and FFA treated with LDN, generally at doses between approximately 2.5 and 4.5 mg daily.

Investigators reported improvements in inflammatory signs or symptoms in some patients and apparent disease stability in many.

Those results are encouraging, but several limitations are important.

The study was retrospective. Many patients were receiving additional therapies. Not every patient had complete information for every symptom or clinical finding.

Disease stability in LPP or FFA also cannot automatically be attributed to one medication because these conditions can fluctuate and, particularly in FFA, may eventually enter periods of spontaneous stabilization.

The study therefore supports continued investigation rather than establishing LDN as proven therapy.

What Did the 2025 Systematic Review Find?

A 2025 systematic review brought together six published reports involving 129 patients with LPP, FFA or overlapping features.

Doses ranged approximately from 2.2 to 4.5 mg daily.

Across the included reports, many patients were described as experiencing improvement in inflammatory signs, symptoms or apparent disease stability. Reported improvements included reductions in erythema, itching, pain and scalp discomfort.

The review therefore supports a genuine clinical signal.

But a systematic review can only be as strong as the studies it contains. Most of the underlying evidence was small, uncontrolled, retrospective or confounded by simultaneous treatment.

The one placebo controlled randomized LPP trial did not establish additional overall benefit.

Response percentages from these pooled observational reports should therefore not be presented to patients as reliable probabilities that LDN will control their disease.

What Do Current Hair Loss Experts Say About LDN?

Current expert guidance reflects the uncertainty in the evidence.

The 2026 European Academy of Dermatology and Venereology Task Force position statement on classic lichen planopilaris describes LDN as a possible adjunctive treatment. It notes that erythema may respond more consistently than several other clinical features while emphasizing the small number of patients studied and frequent mixing of LPP and FFA populations.

Frontal fibrosing alopecia has an even less certain evidence base.

The international SOFFIA expert consensus process did not reach consensus that naltrexone is an effective FFA treatment and did not establish an optimal dose.

These are different forms of guidance and should not be conflated.

LDN may be used by physicians experienced with inflammatory scarring alopecia, but it is not an established first line therapy whose ability to stop permanent follicular destruction has been proven through large randomized trials.

Why Is FFA Particularly Difficult to Study?

Frontal fibrosing alopecia often progresses slowly.

Some patients experience years of gradual recession followed by spontaneous slowing or stabilization. Disease can also reactivate after a period of apparent inactivity.

That natural history makes uncontrolled treatment studies particularly difficult to interpret.

If a patient’s FFA becomes stable while taking LDN, that does not automatically establish that the medication caused the stabilization.

Standardized photographs, measurements and long term observation are therefore especially important when deciding whether treatment is genuinely changing the course of disease.

Does LDN Work for Alopecia Areata?

There is not adequate clinical evidence to say that it does.

Low-dose naltrexone has occasionally been discussed as an unconventional treatment for alopecia areata because AA is an autoimmune disease and LDN has proposed immunomodulatory effects.

That biological rationale is not enough.

There are no convincing modern randomized clinical trials demonstrating that LDN increases scalp hair regrowth or meaningfully controls alopecia areata.

Modern alopecia areata treatment includes substantially stronger evidence for local corticosteroid therapy in limited disease and FDA approved JAK inhibitors for appropriately selected patients with severe disease.

LDN should therefore not be presented as an established treatment for alopecia areata.

The previous AHLA page’s emphasis on alopecia areata should be removed.

Does LDN Work for Male or Female Pattern Hair Loss?

There is no established evidence supporting low-dose naltrexone for ordinary androgenetic alopecia.

Male and female pattern hair loss involve progressive follicular miniaturization rather than the lymphocytic follicular inflammation responsible for disorders such as LPP.

LDN has not been established as an alternative to minoxidil, finasteride or other appropriately selected treatments for pattern hair loss.

A medication described as anti inflammatory should not automatically be assumed to treat every type of hair loss.

What About Telogen Effluvium?

Low-dose naltrexone is not an established treatment for ordinary telogen effluvium.

Telogen effluvium requires investigation of the underlying trigger, which may include illness, medication changes, nutritional deficiency, hormonal changes, substantial physiological stress or other causes.

Adding an immunomodulatory medication without first establishing the cause of diffuse shedding does not address the underlying problem.

What About Other Scarring Alopecias?

LDN should not automatically be generalized from LPP and FFA to every form of scarring alopecia.

Central centrifugal cicatricial alopecia, discoid lupus erythematosus, folliculitis decalvans and other cicatricial alopecias have different biology and treatment considerations.

There is not sufficient evidence to consider LDN an established treatment across these diseases simply because inflammation is involved.

Correct diagnosis is particularly important in scarring alopecia because treatment delays can result in irreversible follicular destruction.

Does LDN Help Scalp Itching or Burning?

Possibly.

One reason LDN has attracted interest in dermatology is its potential effect on itching, pain and dysesthesia.

Some retrospective LPP and FFA studies have reported improvements in itching or scalp discomfort.

Results have not been consistent. The prospective one year LPP and FFA study did not demonstrate statistically significant improvement in itching, burning or pain at 12 months.

Symptom relief is therefore possible but should not be guaranteed.

Symptom improvement should also not automatically be interpreted as proof that inflammatory follicular destruction has stopped.

What Dose Is Used?

There is no FDA approved LDN regimen for hair loss.

Published LPP and FFA studies have most frequently used approximately 3 mg once daily, with doses between roughly 2.5 and 4.5 mg daily also reported.

Broader dermatology literature commonly uses low-dose naltrexone within a similar low single digit milligram range.

There is no good evidence that 4.5 mg is inherently better than 3 mg for scarring alopecia.

There are also no adequate trials establishing that bedtime dosing is superior to morning dosing.

Treatment should therefore be individualized rather than escalated automatically toward the highest commonly used LDN dose.

How Long Does LDN Take to Work?

There is no established treatment timeline.

Published scarring alopecia studies have evaluated patients over periods ranging from several weeks to approximately one year.

Because LPP and FFA are chronic disorders whose activity can change slowly, a few days or weeks is generally insufficient to determine whether disease progression has actually changed.

Response should be evaluated objectively whenever possible using standardized photographs, examination for inflammatory signs and documentation of symptoms and hairline progression.

The physician should establish in advance what would constitute treatment success.

In a scarring alopecia, stabilization can be an important success even if no new hair appears.

How Should LPP or FFA Response Be Measured?

This is particularly important because the primary objective is preventing additional permanent loss.

Useful monitoring can include:

• Standardized scalp and hairline photographs
• Measurements of frontal or temporal hairline recession
• Trichoscopic documentation of perifollicular erythema and scale
• Hair pull testing where appropriate
• Documentation of itching, burning, pain or scalp tenderness
• Disease activity scoring when clinically useful

Subjective impressions alone can be misleading.

A medication that is continued for months because the scalp feels calmer should not automatically be assumed to have stopped ongoing follicular destruction.

Does LDN Have to Be Continued?

We do not know.

There are not adequate discontinuation studies in LPP or FFA defining how long LDN should be continued after apparent disease stability or what percentage of patients relapse when treatment stops.

This is another reason not to present LDN as an established long term maintenance treatment.

If a patient appears to benefit, the physician should periodically reassess whether continued treatment remains necessary and whether objective disease control is actually being maintained.

How Is Low-Dose Naltrexone Obtained?

Standard oral naltrexone is generally supplied at doses much higher than those used for LDN, commonly as 50 mg tablets.

There is no FDA approved low-dose naltrexone formulation specifically for hair disease.

As a result, the 1 to 5 mg doses commonly described as LDN are frequently prepared by a compounding pharmacy as lower dose capsules or liquid formulations.

Compounded medication can serve a legitimate medical purpose, but compounded products do not undergo FDA premarket approval for safety, effectiveness or finished-product quality in the same manner as an approved drug product.

Evidence involving a particular LDN dose does not automatically validate every compounded formulation.

Patients should also not assume that attempting to estimate tiny fractions of a standard tablet at home provides the same dose accuracy as a professionally prepared product.

What Are the Most Common Side Effects?

LDN has generally been manageable in the small dermatology studies published so far, but the frequency of adverse effects has varied substantially among studies.

Reported effects include:

• Vivid or unusual dreams
• Headache
• Sleep disturbance or insomnia
• Nausea
• Abdominal discomfort
• Dizziness
• Anxiety or nervousness
• Fatigue
• Dry mouth

The 2025 systematic review reported adverse events in approximately 18.6 percent of the 129 patients included across the reviewed reports.

In contrast, the prospective one year study recorded at least one adverse event in 14 of 34 patients who took LDN, or approximately 41 percent. Vivid dreams and headache were among the more commonly reported problems, and several patients discontinued treatment because of adverse effects.

Those differing figures show why the exact incidence of LDN side effects should not be considered well established.

Can LDN Cause Hair Loss?

Alopecia has been reported among adverse events in clinical experience with conventional dose naltrexone.

That does not establish that low-dose naltrexone commonly causes hair loss.

There is not a well characterized LDN specific incidence of medication induced shedding.

If diffuse shedding begins after starting LDN, it should not automatically be assumed to represent worsening of the underlying inflammatory alopecia. Medication effects, telogen effluvium, pattern hair loss and other causes may need to be considered.

The Most Important Safety Issue: Opioids

This is the issue every patient considering low-dose naltrexone needs to understand.

Naltrexone blocks opioid receptors.

Standard naltrexone is contraindicated in patients actively receiving opioid analgesics, patients currently dependent on opioids, patients maintained on methadone or buprenorphine and patients in acute opioid withdrawal.

This includes medications such as morphine, oxycodone, hydrocodone, codeine, methadone, buprenorphine and tramadol.

Opioids can also appear in some prescription cough suppressants and antidiarrheal medications, not only in medications patients recognize as painkillers.

The exact degree and duration of opioid blockade produced by 1 to 5 mg LDN are less well characterized than with standard 50 mg naltrexone.

That uncertainty does not make the interaction irrelevant.

A patient should not begin LDN while using an opioid or independently combine the two because the naltrexone dose is described as low.

What Happens if Someone Is Physically Dependent on Opioids?

Naltrexone can precipitate acute opioid withdrawal.

With conventional naltrexone treatment, current prescribing information recommends an opioid free interval of at least 7 to 10 days after short acting opioids before treatment begins.

Patients transitioning from methadone or buprenorphine may remain vulnerable to precipitated withdrawal for as long as approximately two weeks.

Those recommendations were developed for conventional naltrexone treatment, not specifically for 1 to 5 mg dermatologic LDN.

There is no validated hair loss specific opioid washout protocol for low-dose naltrexone.

Someone using or recently dependent on opioids should therefore not simply shorten the standard interval because the planned naltrexone dose is lower.

What if Surgery or Opioid Pain Medication Is Needed?

Patients taking LDN should tell surgeons, anesthesiologists, dentists and emergency physicians that they are taking naltrexone.

Naltrexone can interfere with opioid analgesia.

Broader perioperative guidance for oral naltrexone often recommends withholding the medication for approximately 72 hours before elective surgery when opioid analgesia is expected to be required.

That interval has not been specifically validated for the 1 to 5 mg doses used as dermatologic LDN.

The prescribing physician and anesthesia or surgical team should therefore determine the plan for an individual patient.

Patients should not independently attempt to overcome residual opioid blockade by taking larger amounts of opioid medication.

If emergency opioid analgesia is required while meaningful naltrexone blockade remains, larger opioid doses may sometimes be necessary and respiratory depression can become deeper or more prolonged. That situation requires close medical monitoring by clinicians experienced with opioid and naltrexone pharmacology.

Can LDN Affect the Liver?

Naltrexone is metabolized by the liver, and conventional prescribing information includes warnings about hepatitis and clinically significant liver dysfunction.

The clearest dose related liver toxicity was observed at doses substantially greater than the usual therapeutic dose.

LDN uses much lower exposure, and serious hepatotoxicity has not emerged as a common finding in the small dermatology studies published so far.

That does not establish zero liver risk.

Patients with significant liver disease, viral hepatitis, substantial alcohol related liver injury or other medications capable of affecting the liver deserve additional consideration.

Conventional naltrexone exposure can increase markedly in cirrhosis. Standard pharmacokinetic data have reported approximately fivefold greater exposure in compensated cirrhosis and approximately tenfold greater exposure in decompensated cirrhosis.

Those figures were not generated using dermatologic LDN doses, but they demonstrate why severe liver dysfunction remains relevant even when a low dose is planned.

There is no FDA established liver monitoring protocol specifically for low-dose naltrexone used for hair loss. Baseline or periodic laboratory testing may be appropriate according to individual risk.

What About Kidney Disease?

Naltrexone and especially its major metabolite are excreted substantially through the urine.

Current prescribing information recommends caution in patients with renal impairment, and severe renal impairment has not been adequately characterized.

There are no dedicated low-dose naltrexone hair loss studies defining optimal dosing in significant kidney disease.

Patients with substantial renal impairment should therefore not assume that the low dose makes kidney function irrelevant.

Can LDN Affect Mood or Sleep?

Sleep effects are among the more frequently reported problems with LDN.

Vivid dreams, insomnia and other sleep disturbances have been reported.

Conventional naltrexone labeling also describes reports of depression, suicidal thoughts, suicide attempts and suicide in patients receiving standard naltrexone treatment. A causal relationship has not been established, and many of those patients had underlying alcohol or opioid use disorders associated with substantial baseline psychiatric risk.

There is no convincing evidence that low-dose naltrexone commonly causes serious psychiatric disease.

Nevertheless, substantial new depression, unusual behavioral changes or suicidal thinking should always receive medical attention rather than being dismissed as an expected medication effect.

What About Pregnancy?

There are no studies specifically evaluating low-dose naltrexone for inflammatory hair disease during pregnancy.

Older naltrexone labeling relied heavily on animal data and the absence of adequate controlled human pregnancy trials.

More recent human experience has become somewhat more reassuring. Studies of women receiving naltrexone for opioid or alcohol use disorders have not identified a clear signal of major congenital abnormalities, and recent systematic reviews and small prospective series have reported generally reassuring pregnancy outcomes.

Those data remain limited and come from patients treated for substance use disorders, not women taking 1 to 5 mg LDN for LPP or FFA.

They therefore do not establish reproductive safety for elective dermatologic treatment.

A woman who is pregnant or planning pregnancy should discuss whether LDN should be continued rather than assuming that a low dose automatically establishes safety.

What About Breastfeeding?

Available human data are reassuring.

Current LactMed guidance states that naltrexone is minimally excreted into human milk and that, when a mother requires naltrexone, treatment is not considered a reason by itself to discontinue breastfeeding.

Published measurements using conventional oral naltrexone have estimated infant exposure at approximately 1 percent or less of the maternal weight adjusted dose in the limited data available.

That experience does not create a dedicated safety database for compounded low-dose naltrexone used specifically to treat hair disease.

Because LDN treatment for scarring alopecia is elective and its efficacy remains uncertain, the decision should still be individualized.

Can Children Take LDN for Hair Loss?

There is no established pediatric LDN treatment for hair loss.

Current oral naltrexone prescribing information states that safe use in patients younger than 18 has not been established for its approved oral indications.

There is also no convincing pediatric evidence supporting LDN for alopecia areata, LPP, FFA or other hair disorders.

Use in children should therefore not be extrapolated from adult scarring alopecia case reports or from LDN use in unrelated pediatric conditions.

Who Should Be Especially Cautious With LDN?

Additional caution is appropriate in patients with:

• Current opioid use
• Methadone or buprenorphine treatment
• Recent opioid dependence
• Use of opioid containing cough or antidiarrheal medication
• Anticipated need for opioid pain medication
• Planned surgery or procedures likely to require opioids
• Significant liver disease
• Significant kidney impairment
• Pregnancy or plans for pregnancy
• Significant new psychiatric symptoms
• Multiple medications where interactions or treatment goals need to be reviewed

The opioid issue is qualitatively different from most other precautions because naltrexone directly blocks the pharmacologic effects of those medications.

What Should Be Evaluated Before Starting LDN?

The first question should be whether the patient has a diagnosis for which LDN has any meaningful evidence.

For suspected LPP or FFA, diagnosis should be established through the appropriate combination of clinical examination, trichoscopy and, when necessary, scalp biopsy.

Disease activity and the amount of existing permanent scarring should also be documented.

The physician should review:

• Current and recent opioid use
• Planned procedures or surgery
• Liver and kidney history
• Other medications and supplements
• Pregnancy or reproductive plans
• Baseline symptoms and objective signs of scalp inflammation
• Other treatments already being used for the underlying disease

For a scarring alopecia, standardized photography and objective hairline measurements are particularly important because preservation of existing hair may be a more meaningful endpoint than visible regrowth.

What Should Someone Ask Before Starting Low-Dose Naltrexone?

Useful questions include:

• What type of hair loss am I actually treating?
• What evidence supports LDN for my specific diagnosis?
• Is the goal hair regrowth, symptom relief or disease stabilization?
• Why is LDN being selected instead of or in addition to a better established treatment?
• What dose are we using and why?
• Is there evidence that a higher LDN dose would work better?
• Is the prescription being compounded?
• How will we objectively determine whether treatment is working?
• How long should we try LDN before reassessing it?
• What other treatments will I be using at the same time?
• Do any of my medications contain opioids?
• What happens if I need opioid pain medication?
• What should I do before surgery or dental treatment?
• Do I need liver or kidney testing?
• What side effects should prompt a call to the physician?
• If my disease becomes stable, how long would treatment continue?

The answers should be based on the specific disease rather than on the general reputation LDN has developed online as an anti inflammatory medication.

The AHLA Perspective

Low-dose naltrexone is an interesting and legitimate area of investigation in inflammatory hair disease, but its role has been overstated in some consumer discussions.

It is not a general hair growth drug.

The best available hair specific evidence involves lichen planopilaris and frontal fibrosing alopecia. Small observational studies and case series suggest that LDN may reduce perifollicular redness, itching or scalp discomfort and may help some patients achieve apparent disease stability.

The 2025 systematic review is encouraging enough that the treatment should not simply be dismissed.

But the evidence has important limitations.

Most studies are small. Many patients were receiving other treatments. Some studies combine LPP and FFA even though they are not clinically identical disorders. FFA can eventually stabilize naturally. Symptoms and visible redness do not always correspond perfectly with ongoing follicular destruction.

Most importantly, the only placebo controlled randomized LPP trial did not show that adding LDN 3 mg daily produced greater overall disease improvement than topical clobetasol with placebo.

Current expert guidance reflects that uncertainty. The 2026 EADV position statement describes LDN as a possible adjunct in classic LPP. In contrast, the international SOFFIA consensus process did not reach agreement that naltrexone is effective for FFA or establish an optimal dose.

That is why LDN should currently be viewed primarily as an adjunctive and incompletely proven treatment, not as a replacement for better established anti inflammatory or systemic strategies when scarring alopecia is actively destroying follicles.

The evidence also does not justify the AHLA’s older suggestion that LDN is a meaningful hair regrowth treatment for alopecia areata. That position should be removed.

LDN’s relatively modest dosing, low cost and generally manageable tolerability make it attractive, but apparent safety does not compensate for uncertain efficacy if permanent follicles are being lost while an inadequately effective treatment is continued.

There is also one safety issue that should never be minimized: naltrexone is an opioid antagonist. Even when prescribed at a low dose for dermatologic purposes, opioid use, opioid dependence, upcoming surgery and the possible need for opioid pain medication must be discussed before treatment.

For a patient with LPP or FFA, the objective should not be to add LDN simply because it is inexpensive, compounded or described as immunomodulatory.

The objective is to establish the diagnosis early, document disease activity, preserve follicles before irreversible scarring occurs, select therapies whose expected benefit justifies their risks and objectively determine whether the disease is actually being controlled.

Used for: Alopecia Areata

Selected References

1. U.S. National Library of Medicine. Naltrexone Hydrochloride Tablets: Prescribing Information. Includes opioid contraindications, precipitated withdrawal, hepatotoxicity, renal and hepatic impairment, pregnancy, adverse effects and opioid analgesia precautions. DailyMed Prescribing Information
2. Bai JQA, Geng RSQ, Gupta S, Donovan J. The Efficacy and Tolerability of Low-Dose Naltrexone in the Treatment of Lichen Planopilaris and Frontal Fibrosing Alopecia: A Systematic Review. J Am Acad Dermatol. 2025;93:1638-1640. doi:10.1016/j.jaad.2025.08.076. PubMed
3. Lajevardi V, Salarvand F, Ghiasi M, Nasimi M, Taraz M. The Efficacy and Safety of Oral Low Dose Naltrexone Versus Placebo in Patients With Lichen Planopilaris: A Randomized Controlled Clinical Trial. J Dermatolog Treat. 2022;33:769-773. doi:10.1080/09546634.2020.1774488. PubMed
4. Hamel RK, Chen L, O’Connell C, Mann C. Oral Low-Dose Naltrexone in the Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris: An Uncontrolled Open-Label Prospective Study. Cureus. 2023;15:e34169. doi:10.7759/cureus.34169. PubMed Central
5. Yossef SM, English JC III. Attenuation of Disease Process Following Treatment With Low-Dose Naltrexone in Patients With Frontal Fibrosing Alopecia and Lichen Planopilaris: A Retrospective Study. J Am Acad Dermatol. 2024;91:141-142. doi:10.1016/j.jaad.2024.03.010. PubMed
6. Seyed Jafari SM, Starace M, Katoulis A, et al. Management of Classic Lichen Planopilaris: The EADV Task Force on Hair Diseases Position Statement. J Eur Acad Dermatol Venereol. 2026;40:1306-1317. doi:10.1111/jdv.70379. EADV Position Statement
7. Meah N, et al. Statement From the Frontal Fibrosing Alopecia International Expert Alliance: SOFFIA 2024. J Eur Acad Dermatol Venereol. 2026. doi:10.1111/jdv.20833. SOFFIA Consensus Statement
8. Zhou MH, Elston DM, Morrison BW, Lipner SR. Low-Dose Naltrexone for Treatment of Dermatologic Conditions: A Clinical Review. J Am Acad Dermatol. 2026;94:200-207. doi:10.1016/j.jaad.2025.09.028. PubMed
9. U.S. National Library of Medicine. Naltrexone. Drugs and Lactation Database, LactMed. Updated February 15, 2026. LactMed